


Carboxypeptidase G2 (CPG2) Inhibitor

Cat. No.:	HY-70003		
CAS No.:	192203-60-4		
Molecular Formula:	C ₁₃ H ₁₅ NO ₆ S		
Molecular Weight:	313.33		
Target:	Carboxypeptidase		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

H₂O : 1.43 mg/mL (4.56 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	3.1915 mL	15.9576 mL	31.9152 mL
5 mM	---	---	---
10 mM	---	---	---

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Carboxypeptidase G2 (CPG2) Inhibitor is a novel Carboxypeptidase G2 (CPG2) Inhibitor, Antitumor agents.

REFERENCES

- [1]. Khan, Tariq H.; Eno-Amoquaye, Eburn A.; Searle, Frances et al. Novel Inhibitors of Carboxypeptidase G2 (CPG2): Potential Use in Antibody-Directed Enzyme Prodrug Therapy. *Journal of Medicinal Chemistry* (1999), 42(6), 951-956.
- [2]. Friedlos F, Lehouritis P, Ogilvie L et al. Attenuated Salmonella targets prodrug activating enzyme carboxypeptidase G2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapy. *Clin Cancer Res.* 2008 Jul 1;14(13):4259-66.
- [3]. Schepelmann S, Ogilvie LM, Hedley D et al. Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2. *Cancer Res.* 2007 May 15;67(10):4949-55.
- [4]. Schepelmann S, Hallenbeck P, Ogilvie LM et al. Systemic gene-directed enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2. *Cancer Res.* 2005 Jun 15;65(12):5003-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA